Rezultati - Kejal Parikh

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

    Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States od C. Pelligra, Kejal Parikh, Shien Guo, C. Chandler, Jorge Mouro, Safiya Abouzaid, Sikander Ailawadhi

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Trends in overall survival and costs of multiple myeloma, 2000–2014

    Trends in overall survival and costs of multiple myeloma, 2000–2014 od Rafaël Fonseca, Safiya Abouzaid, Machaon Bonafede, Qizhe Cai, Kejal Parikh, Leon E. Cosler, Paul G. Richardson

    Izdano 2016
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

    Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases od Jipan Xie, M. Namjoshi, Eric Q. Wu, Kejal Parikh, Melissa Diener, Andrew P. Yu, Amy Guo, Kenneth W. Culver

    Izdano 2011
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis

    Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis od Sikander Ailawadhi, Kejal Parikh, Safiya Abouzaid, Zhou Zhou, Wenxi Tang, Zoe Clancy, Claudia Cheung, Zheng‐Yi Zhou, Jipan Xie

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: